Advisory Board

Jacob Cynamon, MD

Jacob Cynamon, MD

Professor of Clinical Radiology, Albert Einstein College of Medicine Chief, Division of Vascular and Interventional RadiologyProgram Director, Vascular and Interventional Radiology Fellowship Program Montefiore Medical Center, Bronx, NY

Jacob CynamonJacob Cynamon

Professor of Clinical Radiology, Albert Einstein College of Medicine Chief, Division of Vascular and Interventional Radiology

Program Director, Vascular and Interventional Radiology Fellowship Program
Montefiore Medical Center, Bronx, NY

Dr. Cynamon is Board Certified in Radiology and in the sub-specialty of Vascular & Interventional Radiology. Dr. Cynamon was named a Top Doctor in New York Magazine’s fifth and tenth-anniversary editions and the past several consecutive years. He has also been named one of the New York Metro Area’s Top Doctors on six different occasions, and was recognized with Patients’ Choice and Castle Connolly Top Doctor awards. He is one of America’s leading experts on Abdominal Aortic Aneurysms, Iliac Aneurysms, Peripheral Arterial Occlusive Diseases, Venous Disease, Dialysis Grafts and Fistulae Management. His current interests are helping patients with uterine fibroids and cancer patients using minimally invasive techniques. He is committed to addressing difficult medical problems and finding better solutions. In addition to Dr. Cynamon being the Section Chief at Montefiore for the past 18 years, he continues to be the fellowship program director. The trainees all leave the program with a sense of accomplishment and a drive to continue learning and establishing themselves as leaders in their field.

Dr. Cynamon began his career in health care more than three decades ago after earning his medical degree from Albert Einstein College of Medicine and completing his fellowship in Interventional Radiology under the direction of Dr. Thomas A. Sos. Dr. Cynamon then accepted a position at Montefiore Medical Center, the University Hospital for Albert Einstein College of Medicine, where he remains today.

Dr. Cynamon was the first physician to perform a Transjugular“Lyse and Wait” procedure for declotting thrombosed dialysis grafts. He also published one of the first reports of the Power Pulse Spray technique for the management of DVT.  He is the lead author or contributor to over 50 peer-reviewed articles, multiple book chapters and solicited reviews. He is a speaker at many international symposiums, including Interventional Radiology, Vascular Surgery, Interventional Cardiology and Nephrology meetings. He has published and presented on the ability to visualize Drug Eluting Beads on CT immediately post embolization. This was initially not recognized, but now is considered obvious.

In 1992 Dr. Cynamon established a symposium, held annually in NYC, to educate practicing interventional radiologists and trainees. Now in its 25th year, the AIM symposium remains an important yearly educational experience. Dr. Cynamon along with Dr. Frank Veith, Dr. Michael Marin, Dr. Juan Parodi and Dr. Claudio Schonholtz performed the first endovascular AAA repair in the United States. This occurred immediately after Dr. Parodi attended the Vascular Surgery and Interventional Radiology Symposiums in NY. Endovascular procedures have continued to evolve. Many of the new techniques were described by Dr. Cynamon and his colleagues in publications and at the NY Vascular or IR meetings. Dr. Cynamon is a member of the American Board of Radiology and a Fellow of the Society of Interventional Radiology.

Mike Pishvaian, MD, PhD

Mike Pishvaian, MD, PhD

Associate Professor, Department of Oncology Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital Johns Hopkins University School of Medicine

Mike Pishvaian, MD, PhDMike Pishvaian, MD, PhD

Associate Professor, Department of Oncology Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine

Dr. Pishvaian is Associate Professor in the Department of Oncology, and Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital at Johns Hopkins University School of Medicine.

Formerly, Dr. Pishvaian was Associate Professor, in the Department of Gastrointestinal Oncology, and Co-director for Clinical Research at the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research at the University of Texas, MD Anderson Cancer Center.

Dr. Pishvaian is an MD and a PhD in Tumor Biology and earned both degrees at Georgetown in 2001. He remained at Georgetown after graduation, completing his medical residency in 2004, then his fellowship in Hematology/Oncology in 2007. He served on the faculty at Georgetown until moving to MD Anderson in 2019.

Dr. Pishvaian is a translational oncologist, focused on providing novel therapy for patients, particularly in the areas of pancreatic cancer and refractory colorectal cancer. His work has been focused in the area of precision medicine, with a special focus on therapy targeted towards homologous recombination DNA repair deficient tumors, and Dr. Pishvaian is a Co-investigator on an NIH RO1 to study mechanisms of resistance to PARP inhibitor-based therapy.

Peter Muscarella, MD

Peter Muscarella, MD

Director, Pancreatic Surgery General Surgery Site Director, Weiler HospitalAssociate Program Director, General Surgery Residency Training Program Montefiore Medical Center, Bronx, NY

Peter Muscarella, MDPeter Muscarella, MD

Director, Pancreatic Surgery
General Surgery Site Director, Weiler Hospital

Associate Program Director, General Surgery Residency Training Program
Montefiore Medical Center, Bronx, NY

Peter Muscarella II, MD received his undergraduate degree in Microbiology from the University of Rochester and his MD from New York Medical College. He completed his residency training in General Surgery at The Ohio State University during which time he performed a two-year research fellowship in pancreatic cancer genetics. Dr. Muscarella was an Associate Professor of Surgery with Tenure at The Ohio State University prior to taking his current position as Director of Pancreatic Surgery at Montefiore Medical Center. His clinical and research interests focus specifically on surgery of the pancreas, bile ducts, and upper gastrointestinal tract. Dr. Muscarella has extensive experience in advanced open minimally invasive surgical procedures for the management of pancreatic disorders, such as pancreatic cancer, pancreatic cysts, and acute & chronic pancreatitis. Dr. Muscarella has co-authored numerous peer-reviewed articles and book chapters. He maintains a busy pancreatic surgery practice and is active in a number of national surgical organizations and committees.

Karyn A. Goodman, MD, MS

Karyn A. Goodman, MD, MS

Professor and Vice Chair of Clinical Research, Department of Radiation Oncology, Icahn School of Medicine at Mount SinaiAssociate Director of Clinical Research, The Tisch Cancer Institute at Mount Sinai

Karyn A. Goodman, MD, MSKaryn A. Goodman, MD, MS

Professor and Vice Chair of Clinical Research, Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai

Associate Director of Clinical Research, The Tisch Cancer Institute at Mount Sinai

Dr. Goodman is a board-certified radiation oncologist specializing in cancers of the gastrointestinal tract, including malignancies of the esophagus, stomach, pancreas, and liver as well as colorectal and anal cancers. She recently joined the Icahn School of Medicine at Mount Sinai as a Professor in the Department of Radiation Oncology and Associate Director of Clinical Research in the Tisch Cancer Institute. Dr. Goodman had been at the University of Colorado Cancer Center for four years after serving as the head of Gastrointestinal Radiation Oncology at Memorial Sloan-Kettering Cancer Center for over eight years. Her initial faculty position was in the Department of Radiation Oncology at Stanford University School of Medicine.

Dr. Goodman obtained her undergraduate and medical degrees from Stanford University and spent a year as a Research Fellow at the Division of Reproductive Health of Centers for Disease Control in Atlanta. She completed her residency training in Radiation Oncology at Memorial Sloan-Kettering Cancer Center where she served as Chief Resident. She earned a Masters in Epidemiology at the Harvard School of Public Health in 2006.

Dr. Goodman’s interests include image-guide radiation therapy, stereotactic body radiotherapy, and intensity-modulated radiotherapy treatment planning for gastrointestinal cancers with the intent of reducing toxicity and improving results with radiation therapy. She has also focused her research on quality of life and late effects after radiotherapy. In addition to her interest in technical advances in radiation oncology, she is involved in the development of therapeutic protocols combining radiation, chemotherapy, and targeted agents for gastrointestinal cancers. She has been selected for inclusion in Castle Connolly’s list of America’s Top Doctors for several years.

Dr. Goodman is an internationally recognized expert in Gastrointestinal Cancer and has served in numerous leadership roles on multiple ASTRO, ASCO, and RTOG/NRG committees. She serves as the national Radiation Oncology principal investigator of the RTOG/NRG 0848 study, a phase III trial evaluating the use of post-operative radiotherapy for pancreatic cancer. She is the national Study Chair for the recently completed CALGB/Alliance Cooperative Group phase II trial (CALGB 80803) investigating PET scan-directed therapy for esophageal cancer. She has published over 100 peer-reviewed articles, review articles, and chapters.

In addition to clinical activities in the area of GI cancers, she is assuming the role of Medical Director of the Clinical Trials Office of the University of Colorado Cancer Center and also serves as Associate Medical Director of the UC Health Oncology Services line.

Daniel D. Von Hoff, MD, FACP

Daniel D. Von Hoff, MD, FACP

Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute)Chief Scientific Officer for US Oncology and for HonorHealth’s Clinical Research InstituteClinical Professor of Medicine, University of Arizona, Tucson, AZ

Daniel D. Von Hoff, MD, FACPDaniel D. Von Hoff, MD, FACP

Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute)

Chief Scientific Officer for US Oncology and for HonorHealth’s Clinical Research Institute
Clinical Professor of Medicine, University of Arizona, Tucson, AZ

Dr. Von Hoff is currently Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for HonorHealth’s Clinical Research Institute. He is also a Clinical Professor of Medicine, University of Arizona.

Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute. Von Hoff became a professor in the departments of medicine and cellular and structural biology at the University of Texas Health Science Center, San Antonio. In 1989, he became the founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and 10 years later he became the director of the cancer center and professor of medicine at the University of Arizona.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

Dr. Von Hoff has published more than 648 papers, 138 book chapters and over 1085 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement inpatient care.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Reza Malek, MD, MSc

Reza Malek, MD, MSc

Neurointerventional Radiologist, Minimally Invasive Surgical Solutions San Jose, CA

Reza Malek, MD, MScReza Malek, MD, MSc

Neurointerventional Radiologist, Minimally Invasive Surgical Solutions
San Jose, CA

Dr. Malek completed medical school at Jefferson Medical College of Thomas Jefferson University in 1991 and continued his internship and a Diagnostic Radiology residency at the Medical Center of Delaware, a Thomas Jefferson University affiliate. He completed a Cardiovascular and Interventional Radiology fellowship at Brigham and Women’s Hospital/Harvard Medical School in 1997. Previously, Dr. Malek was the Chief of Interventional Radiology at Riverside Community Hospital and St. Mary’s Regional Medical Center for five years as well as the Assistant Clinical Professor at the University of California, Irvine Medical Center. In 2001, he was the acting Chief of Interventional Radiology at the University of California, Irvine Medical Center and continued as a part-time fellow in NeuroInterventional Radiology. In 2003, Dr. Malek completed an additional year of fellowship in Endovascular Neurosurgery at the University of California, San Francisco. He completed the Master’s degree program in Neurovascular Diseases at SUD University in Paris under a pioneer of the field, Professor Pierre Lasjunias, MD. Dr. Malek is a full member of the Society of Interventional Radiology and the Society of NeuroInterventional Surgery. He was the first physician to bring Endovascular Neurosurgery to San Jose, California and has developed one of the most dynamic stroke programs in the country. Dr. Malek specializes in all aspects of Peripheral Vascular Disease, Endovascular Neurosurgery and is active in teaching, research, and publishing in this field.

Menu